Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Sigma ligands for neuronal regeneration and functional recovery

a neuronal regeneration and functional recovery technology, applied in the field of treatment, can solve problems such as paralysis, speech problems, dementia, etc., and achieve the effect of enhancing functional recovery and neuronal regeneration

Inactive Publication Date: 2005-01-27
MS SCI CORP
View PDF5 Cites 38 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides methods and compositions for treating neurodegenerative diseases. The sigma receptor ligands of the invention enhance functional recovery and neuronal regeneration. These molecules can be delivered alone or in combination with additional agents, and are used as neuronal regeneration agents for the treatment of neurodegenerative diseases such as those resulting from ischemic strokes or other insults that injure neurons.

Problems solved by technology

Depending on the area of the brain that is damaged, a stroke can cause coma, paralysis, speech problems and dementia.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sigma ligands for neuronal regeneration and functional recovery
  • Sigma ligands for neuronal regeneration and functional recovery

Examples

Experimental program
Comparison scheme
Effect test

example 1

Animal Models for Neuronal Regeneration (Functional Recover)

Male 3 months old SHR (spontaneous hypertensive) rats are used for induction of stroke by MCA occlusion. This is the preferred strain since most stroke patients are hypertensive. The animals are anesthetized with Methohexital and a small craniectomy is made above the zygmotic arch to expose the middle cerebral artery, which is occluded with a 10-0 monofilament nylon thread distal to the origin of the striatal branches. The rats are not intubated and no catheters are inserted. Following MCA occlusion a large and reproducible infarct is obtained, leading to a robust sensorimotor deficit. The animals are kept on a 6 hr light / 18 h dark cycle with free access to food and water. At two days after the MCAO the rats are treated with the compound I, II, III, IV, V, VI, VII, VIII, or IX (0.03-10 mg / kg) s.c. or p.o. and a control group is given saline for 2-8 weeks. At 2, 4, 6 and 8 weeks animals are tested in the rotating pole or ...

example 2

Evidence of Neuronal Regeneration in Rats Treated with SA4503

1. Rotating Pole

Thirty five spontaneously hypertensive rats were exposed to permanent middle artery occlusion (MCAO), then divided into three treatment groups. Starting at two days after occlusion and continuing daily until 28 days after occlusion, SA4503 was administered s.c. in doses of 0.3 mg / kg (12 rats) or 1.0 mg / kg (12 rats). In a control group (11 rats), vehicle only was administered. At the start of treatment, and at several time points during the test, the rats were assessed for their performance in the rotating pole model. This model is described in Example 1. It requires the rats to cross a horizontally suspended rotating pole having a length of 1 m. This task measures the sensory-motor performance of the animals. The animals' behaviour was recorded using a video camera and later analyzed and scored by a trained technician. The scoring ranges from 0 to 6, with 0 being very poor performance and 6 reflecting t...

example 3

Evidence of Neuronal Regeneration in Rats Treated with Siramesine

1. Morris Water Maze

The Morris water maze was used to assess functional recovery, in-particular recovery in a cognitive skill, in spontaneously hypertensive rats after exposure to permanent middle artery occlusion (MCAO), a model of ischemic stroke.

Forty three spontaneously hypertensive rats were exposed to permanent middle artery occlusion (MCAO). Starting at two days after occlusion and continuing for 14 days, Siramesine was administered p.o. in doses of 0.3 mg / kg (14 rats) or 1.0 mg / kg (14 rats). In a control group (15 rats), vehicle only was administered. On day 35 after permanent MCAO, the rats were assessed for their performance in the Morris Water Maze Test.

In the test, the rats were given a series of 6 trials, 1 hour apart in a large dark-colored tank (200 cm in diameter) filled with clear water at a temperature of 22.0±1.5° C. A 12×12-cm submerged platform (2 mm below the water surface) was placed in t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Login to View More

Abstract

The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptors. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by ischemic stroke, diabetic peripheral neuropathy, cancer therapy induced neuropathy, multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, spinal cord injury, Huntington's disease or Parkinson's disease. In other methods, the sigma receptor ligands are administered after stroke to facilitate functional recovery. The administration of the sigma receptor ligands effects faster functional recovery.

Description

FIELD OF THE INVENTION The present invention relates to methods of treatment to achieve neuronal regeneration in subjects with neurodegenerative disorders. In particular, the present invention relates to the use of sigma receptor ligands to facilitate neuronal regeneration and functional recovery in subjects after neurodegenerative disease. BACKGROUND OF THE INVENTION The existence of the sigma receptor was proposed by Martin et al. (1976) J. Pharmacol. Exp. Ther. 197: 517-532 to explain the psychotomimetic effects of benzomorphans. Initially, the sigma receptor was thought to be a novel opioid receptor. However, the binding of the benzomorphans to the sigma receptor is not antagonized by naloxone, the classic opioid receptor antagonist. Further, the benzomorphans bind to a site that is distinct from the phencyclidine receptor on the N-methyl-D-aspartate (NMDA) receptor complex. Thus, the sigma receptor is established as a unique receptor. The sigma receptor consists of two subty...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/00A61K31/195A61K31/438A61K31/473A61K31/485A61K31/495A61K38/17C07D295/096G06F21/00H04L29/06
CPCA61K31/00C07D295/096A61K31/495A61K31/438A61P3/10A61P9/10A61P21/02A61P25/00A61P25/02A61P25/14A61P25/16A61P25/28A61P43/00
Inventor OKSENBERG, DONNARICKHAG, MATTIASSHAMLOO, MEHRDADNIKOLICH, KAROLYURFER, ROMANWIELOCH, TADEUSZ
Owner MS SCI CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com